Logo
Logo

About Palbociclib API

Product
  • Therapeutic CategoryAnti-Cancer/ Oncology

  • CAS Number

    571190-30-2

  • API Technology

    Synthetic

  • Dose Form

    Capsule/ Tablet, Oral Solids

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    Brazil DMF, USDMF, Singapore DMF

Mechanism of Action

It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.

Indication

IBRANCE is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:

  • An aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or
  • Fulvestrant in women with disease progression following endocrine therapy.

Related APIs

Abiraterone Acetate

Anti-Cancer/ Oncology

arrow

Adagrasib

Anti-Cancer/ Oncology

arrow

Apalutamide (Amorphous & Form B)

Anti-Cancer/ Oncology

arrow

Azacitidine

Anti-Cancer/ Oncology

arrow

Bendamustine Hydrochloride

Anti-Cancer/ Oncology

arrow

Bortezomib

Anti-Cancer/ Oncology

arrow

Cabazitaxel

Anti-Cancer/ Oncology

arrow

Cabozantinib HCl

Anti-Cancer/ Oncology

arrow

Cabozantinib S-Malate

Anti-Cancer/ Oncology

arrow

Capecitabine

Anti-Cancer/ Oncology

arrow

Carfilzomib

Anti-Cancer/ Oncology

arrow

Darolutamide

Anti-Cancer/ Oncology

arrow

Dasatinib (Monohydrate)

Anti-Cancer/ Oncology

arrow

Decitabine

Anti-Cancer/ Oncology

arrow

Deucravacitinib

Anti-Cancer/ Oncology

arrow

Enzalutamide

Anti-Cancer/ Oncology

arrow

Eribulin (Available For Selected Markets)

Anti-Cancer/ Oncology

arrow

Fosaprepitant

Anti-Cancer/ Oncology

arrow

Fruquintinib

Anti-Cancer/ Oncology

arrow

Gemcitabine Hydrochloride

Anti-Cancer/ Oncology

arrow

Granisteron

Anti-Cancer/ Oncology

arrow

Lenalidomide (Form A)

Anti-Cancer/ Oncology

arrow

Lenvatinib Mesylate ( MIBK Solvate)

Anti-Cancer/ Oncology

arrow

Lenvatinib Mesylate (Form-C)

Anti-Cancer/ Oncology

arrow

Lomustine

Anti-Cancer/ Oncology

arrow

Midostaurin

Anti-Cancer/ Oncology

arrow

Nilotinib Hydrochloride Monohydrate (Form B)

Anti-Cancer/ Oncology

arrow

Niraparib Tosylate

Anti-Cancer/ Oncology

arrow

Olaparib (Form A)

Anti-Cancer/ Oncology

arrow

Palbociclib

Anti-Cancer/ Oncology

arrow

Pazopanib

Anti-Cancer/ Oncology

arrow

Pemetrexed Disodium Heptahydrate

Anti-Cancer/ Oncology

arrow

Pirtobrutinib

Anti-Cancer/ Oncology

arrow

Pomalidomide

Anti-Cancer/ Oncology

arrow

Relugolix

Anti-Cancer/ Oncology

arrow

Ripretinib

Anti-Cancer/ Oncology

arrow

Ritlecitinib

Anti-Cancer/ Oncology

arrow

Ruxolitinib Phosphate

Anti-Cancer/ Oncology

arrow

Tucatinib

Anti-Cancer/ Oncology

arrow

Venetoclax

Anti-Cancer/ Oncology

arrow

Zanubrutinib

Anti-Cancer/ Oncology

arrow

Zoledronic Acid

Anti-Cancer/ Oncology

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone

Related Resources

Palbociclib – how a novel process development approach provides IP advantages

Palbociclib – how a novel process development approach provides IP advantages

This whitepaper outlines how Dr. Reddy's holistic development approach can help our API partners across geographies to provide patients early access to the generic alternative of Palbocicilb while gaining or maintaining competitive advantages.Our team of process experts draw on their integrated understanding of IP, process development (API and formulation), and API manufacturing to ensure that by design the process is lean, free from potential genotoxic impurities and  scalable to manufacture for early market entries.To continue on reading our latest whitepaer please fill the contact form below :You can also explore our Palbocicilb API offering by clicking on the link below:https://api.drreddys.com/product/palbociclib
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.